Kornimate/medical-research-clean huggingface dataset:
surgical treatment of a chronic anal fissure

Conditions: Chronic Anal Fissure

Summary: this study is aimed at studying the effectiveness and safety of surgical treatment of chronic anal fissure.

a chronic anal fissure is a rupture of the mucous membrane of the anal canal, lasting more than 2 months and resistant to non-surgical treatment. this condition is accompanied by a strong pain syndrome during and after defecation (defecation). this condition is most often found in young and able-bodied adults, so the issue of treatment is of particular relevance. the main cause of the development of a chronic anal fissure is a spasm of the internal sphincter. it should be eliminated first of all to ensure effective therapy.the investigators plan to treat a chronic anal fissure by performing a lateral subcutaneous sphincterotomy, without excision of the fissure.

Eligibility criteria:
inclusion criteria: * patients with chronic anal fissure exclusion criteria: * inflammatory diseases of the colon * pectenosis * previous surgical interventions on the anal canal * iv grade internal and external hemorrhoids * rectal fistula * severe somatic diseases at the decompensation stage * pregnancy and lactation * anal sphincter insufficiency
a study of 1592u89 in hiv-infected children

Conditions: HIV Infections

Summary: the purpose of this study is to see if it is safe to give 1592u89 to children (aged 6 months until 14th birthday) with advanced hiv infection who have few treatment options available. the study also examines the effect 1592u89 has on the levels of hiv in the blood.

this is an open-label, non-randomized study. all patients will be treated with 1592u89. additionally, since optimal therapy usually includes the combined use of 2 or more antiretroviral agents in advanced patients, other novel antiretroviral therapies may be accessed through commercial means or via compassionate use programs. note: 1592u89 should not be administered as a single new agent added to a failing treatment regimen.

Eligibility criteria:
inclusion criteria concurrent medication: allowed: * intravenous immunoglobulin g. * erythropoietin, granulocyte colony stimulating factor and granulocyte macrophage colony stimulating factor, for the management of hematologic toxicity. patients must have: * documented hiv infection. * high risk for disease progression or mortality as defined by either of the following: * viral load \> 100,000 copies/ml and cd4 cells \< 15% of total lymphocyte count despite at least 4 weeks of therapy with commercially available antiretrovirals or as a result of no therapy due to treatment-limiting toxicity of zdv, 3tc, and ddi; or hiv-associated encephalopathy refractory to zdv-containing regimen. * no access to any 1592u89 pediatric study where the patient could qualify for inclusion. * parent or legal guardian with the ability to understand and provide written consent for the patient to participate in the trial. study patients over 13 years should also give written informed consent whenever possible. exclusion criteria co-existing condition: patients with any of the following symptoms or conditions are excluded: * in the investigator's opinion, the patient is unlikely to comply with the requirements of the study. * renal failure requiring dialysis. * hepatic failure evident by grade 3 or 4 hyperbilirubinemia and ast \> 10 x upper limits of normal. * life-threatening infection or other chronic disease that may interfere with taking 1592u89 or compromise the patient's safety. patients with the following prior conditions are excluded: documented hypersensitivity to 1592u89 or any other nucleoside analogue. see inclusion - general criteria.

Keywords: hiv-1 cd4 lymphocyte count reverse transcriptase inhibitors anti-hiv agents viral load abacavir
evaluation of the potential effects of lrp5 and tph1 in the pathogenesis of periodontal disease individuals with stage iii grade b periodontitis

Conditions: Periodontal Disease; Periodontitis (Stage 3); Periodontitis Stage III

Summary: objectives: the aim of this study was to determine the changes in lrp5 and tph1 levels in serum and saliva samples due to periodontal inflammation and to evaluate the relationship between these values and clinical periodontal parameters. methods: saliva and serum samples were collected from 20 systemically healthy patients with stage iii periodontitis and 20 periodontally healthy control individuals. salivary and serum lrp5 and tph1 levels were analyzed using enzyme-linked immunosorbent assay (elisa). clinical periodontal parameters, including plaque index (pi), probing pocket depth (ppd), bleeding on probing (bop), and clinical attachment level (cal), were recorded.


Eligibility criteria:
inclusion criteria: * \>18 years old, * at least 16 permanent teeth except 3rd molars, * individuals who do not use orthodontic appliances, * individuals who are not pregnant or lactating, * individuals without any systemic disease that may affect periodontal health, * systemically healthy individuals, * individuals who have not used anti-inflammatory and/or anti-microbial drugs in the last 6 months, * individuals who have not received periodontal treatment in the last 1 year exclusion criteria: * pregnant/lactating individuals, * individuals who have used anti-inflammatory and/or anti-microbial drugs in the last 6 months, * individuals who have undergone periodontal treatment in the last 1 year, * individuals with psychiatric illness, * individuals with any oral infection, * individuals with \<16 teeth, excluding molars, * individuals with alcohol dependence, * individuals with active infectious disease (acute hepatitis, aids, tuberculosis), cancer or any systemic condition that may affect periodontal tissues, * individuals receiving treatment with drugs known to affect periodontal tissues (phenytoin, cyclosporine a, calcium channel blockers)

Keywords: low-density lipoprotein receptor-associated protein 5 tryptophan hydroxylase 1 periodontitis
study evaluating zr-panitumumab for assessment of suspected metastatic lesions on 18f-fdg-pet/ct in head and neck squamous cell carcinoma

Conditions: Head-and-neck Squamous Cell Carcinoma

Summary: the purpose of this study is to determine the diagnostic utility of 89zr-panitumumab to identify metastatic lesion(s) in subjects with head and neck squamous cell carcinoma (hnscc).

primary objective(s): - determine the sensitivity and specificity of 89zr-panitumumab for the detection of suspected metastatic lesions secondary objective(s): - compare sensitivity and specificity of 18f-fdg-pet/ct and 89zr-panitumumab-pet/ct for detection of suspected metastatic lesions

Eligibility criteria:
inclusion criteria: * age ≥ 19 years. * biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck. * subjects diagnosed with any t stage, any subsite within the head and neck. subjects with recurrent disease or a new primary will be allowed. * must have standard of care 18f-fdg-pet/ct scan ≤ 30 days of day 0 with suspected metastatic lesions. * have acceptable hematological status, coagulation status, kidney function, and liver function including the following clinical results: * hemoglobin ≥ 9gm/dl * white blood cell count \> 3000/mm3 * platelet count ≥ 100,000/mm3 * serum creatinine ≤ 1.5 times upper reference range * ptt = 11.5 - 14.4 seconds * inr = 0.9 - 1.2 exclusion criteria: * myocardial infarction (mi); cerebrovascular accident (cva); uncontrolled congestive heart failure (chf); significant liver disease; or unstable angina within 6 months prior to enrollment * history of infusion reactions to other monoclonal antibody therapies * pregnant or breastfeeding * magnesium or potassium lower than the normal institutional values * subjects receiving class ia (quinidine, procainamide) or class iii (dofetilide, amiodarone, sotalol) antiarrhythmic agents * subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis * severe renal disease or anuria * known hypersensitivity to deferoxamine or any of its components
development of a new immunochemistry method using antibodies of proteins related pancreatic cancer

Conditions: Pancreatic Cancer

Summary: identifying the malignancy of pancreatic mass using endoscopic ultrasound-guided fine-needle aspiration (eus-fna) is important for treatment decision-making and prognosis prediction. the sensitivity of eus-fna cytology specimens based on papanicolaou (pap) staining is low, which hampers accurate diagnosis of pancreatic mass. we assessed the diagnostic value of immunohistochemical (ihc) and immunofluorescence (if) staining for methionyl-trna synthetase 1 (mars1).

background / aims: the sensitivity of endoscopic ultrasound-guided aspiration cytology used to distinguish the pancreatic mass is low and clinical usefulness is not secured. the aim of this study was to evaluate clinical efficacy of a new differential staining method for cytology which is difficult to differentiate by the conventional staining method using pancreatic cancer related protein expressed only in pancreatic cancer. hypothesis: the statistical significance between conventional staining method and mars1 staining in the pancreatic cancer cells collected by endoscopic ultrasound-guided aspiration will be compared to prove the usefulness of the new staining method. clinical study design: the expression of mars1 in the pancreatic cancer cell line obtained by endoscopic ultrasound in patients suspected of having pancreatic cancer using immunofluorescence or immunohistochemistry staining will be performed to differentiate the presence of the tumor. the sensitivity and specificity of the new staining method will be compared with the conventional staining method and its usefulness be confirmed.

Eligibility criteria:
inclusion criteria: 1. patients with pancreatic cancer confirmed by imaging (ct, mri, pet-ct) 2. patients with pancreatic cancer diagnosed using cytology by endoscopic ultrasound 3. patients who underwent surgical treatment with pancreatic cancer exclusion criteria: 1. minors under the age of 19, vulnerable subjects such as illiteracy 2. excludes necrotic specimens 3. samples with non-diagnostic cytology results and insufficient cells for further evaluation 4. samples classified as neoplastic (benign or other)
mental stress & diesel exhaust on cardiovascular health

Conditions: Blood Pressure; Inflammation; Catecholamines

Summary: this study uses an experimental design to conduct a double-blind, randomized, crossover study where participants receive both diesel exhaust and a mental stress test in a controlled setting. my hypothesis is that the synergistic effect of stress and air pollution will result in higher levels of stress and inflammation (measured via biological markers) as well as poorer cardiovascular disease related outcomes compared to the independent effect of each exposure separately.


Eligibility criteria:
inclusion criteria: non-smokers without history of high blood pressure, asthma, diabetes, high cholesterol, post-traumatic stress disorder (ptsd) or any other chronic condition that requires ongoing care. exclusion criteria: 1. smoking: we rule out active smoking by checking urine cotinine during our study. 2. history of high blood pressure: we objectively measure bp during in-person screening and exclude those with blood pressure (\>130/85 mmhg). 3. asthmatic: spirometry is done at screening to rule out asthma. 4. diabetic: we obtain fasting blood sugar to rule out diabetes at screening (\>125 mg/dl) 5. cholesterol: we obtain fasting blood lipid levels to rule out hypercholesterolemia at screening (\>200 mg/dl). 6. history of ptsd: subjects will be asked about prior ptsd diagnosis during the phone and in person screen. 7. any other chronic condition requiring ongoing care based on medication use. 8. a body mass index (weight in kilograms divided by height in meters squared) greater than 26 and less than 18.5 9. a female of childbearing age with a positive pregnancy test 10. a female of childbearing age who is unwilling to use effective contraception during the study
observational study in type 2 diabetics treated by an intensive insulin treatment of levemir®

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this study is conducted in europe. the aim of this observational study is to gain practical experience with once daily levemir® administration in type 2 diabetes patients who were previously treated with nph insulins (e.g. protaphane®) as basal insulin as part of their iit under normal clinical practice conditions in lithuania


Eligibility criteria:
inclusion criteria: * type 2 diabetic subjects on intensive insulin treatment (iit) * eligibility for once daily insulin detemir administration * informed consent obtained before any observation-related activities exclusion criteria: * known or suspected allergy to insulin detemir * subjects previously enrolled in the observation * women who are pregnant, breast feeding or have the intention of becoming pregnant within 6 months
paclitaxol every 2 week versus paclitaxol every 1 week in the adjuvant treatment of breast cancer

Conditions: Breast Cancer; Paclitaxel; Epirubicin; Cyclophosphamide

Summary: rationale: adjuvant chemotherapy has been proven to reduce significantly the risk for relapse and death in women with operable breast cancer.in the north american inter-group factorial trial design (calgb 9741) the concept of dosedense adjuvant chemotherapy was further tested in patients with node-positive breast cancer.weekly paclitaxel after standard adjuvant chemotherapy with epirubicin and cyclophosphamide improves disease-free and overall survival in women with breast cancer.investigators asked if dose-dense 2-week intertreatment intervals (supported by the use of granulocyte-colony stimulating factor) were better than the conventional inconvenient weekly intervals.


Eligibility criteria:
inclusion criteria: 1. age between 18-70 years female operable breast cancer patients 2. patients were required to register within 60 days from the final surgical procedure required to adequately treat the invasive primary tumor. 3. women who had operable,histologically confirmed adenocarcinoma of the breast with a. histologically involved positive lymph nodes b. or histologic diagnosis for three negative patients; c. or lymph node negative, her2 positive(if her2 + +, fish (fluorescence in situ hybridization method)/cish tests confirmed her2 amplification is positive),but unable or intolerant to herceptin combined chemotherapy. 4. karnofsky points greater than or equal to 70. 5. postmenopausal women or hcg test results were negative, women of child-bearing potential willing to use effective contraception during the study. 6. patient characteristics: hematopoietic: * neutrophil count at least 1,500/mm\^3 * platelet count at least 100,000/mm\^3 hepatic: * bilirubin no greater than 1.5 times upper limit of normal * tbil no greater than 1.5 times upper limit of normal * akp no greater than 2.5 times upper limit of normal * ast no greater than 2.5 times upper limit of normal * alt no greater than 2.5 times upper limit of normal renal: * creatinine no greater than 1.5 times upper limit of normal cardiovascular: * no history of myocardial infarction * no congestive heart failure * no significant ischemic or valvular heart disease other: * no other prior invasive malignancies within the past 5 years except curatively treated basal or squamous cell skin cancer or carcinoma in situ of the cervix * no hypersensitivity to paclitaxel or docetaxel or other similarly formulated drugs (with cremophor or polysorbate) other protocol-defined inclusion/exclusion criteria may apply. exclusion criteria: -
zimmer activbraid rotator cuff repair (rcr) study

Conditions: Rotator Cuff Repair of the Shoulder

Summary: we will enroll up to 65 patients undergoing primary arthroscopic rotator cuff repair (rcr) using activbraid™collagen co-braid suture (zimmer biomet) and evaluate rcr healing as well as shoulder range of motion, strength, and patient-reported outcomes at 6m, 1y and 2y.


Eligibility criteria:
inclusion criteria: * 18-75 years * acute or chronic, reparable, 1-5 cm full thickness tear of the supraspinatus and/or infraspinatus tendons exclusion criteria: * prior ipsilateral shoulder surgery * outstanding worker's compensation claim * symptomatic cervical spine disease * a frozen shoulder * advanced glenohumeral arthritis * isolated subscapularis tear * significant radiation exposure for other medical reasons. * known is advance to be claustrophobic * known history of hypersensitivity to bovine-derived materials.

Keywords: rotator cuff repair shoulder rotator cuff tear collagen suture
ventilatory functions, oxygen saturation, and quality of life response to long time cement dust exposure

Conditions: Occupational Diseases

Summary: thousands of people are working daily in a dusty environment. many studied reported respiratory symptoms and ventilatory disorders among factory workers who exposed to cement dust. but the evidence for respiratory effect and daily activities over a long time of cement dust exposure has not been conclusive

a total of 49 subjects working in a cement production factory were assessed and divided into three groups according to the total period of work exposure. groupe a (18 subjects) with work period \ 15 years. the ventilatory functions, oxygen saturation, and quality of life were assessed in the three groups. results: the study results revealed a statistically significant difference between the three groups in the mean values of fvc (%), fev1/fvc (%), spo2.

Eligibility criteria:
inclusion criteria: * the ages were between 25 to 50 years old. * the body mass index ranged from (18,5 - 29,9) kg/m2. exclusion criteria: * age less than 25 or more 50. * any chronic diseases * severe musculoskeletal and cardiopulmonary disorders and * class iii obesity (35-39.9 kg/m 2) or more
remote programming for deep brain stimulation in parkinson's disease.

Conditions: Deep Brain Stimulation; Parkinson Disease

Summary: this study aims to conduct a randomized controlled study to compare the efficacy of remote programming (rp) on the improvement of motor function after dbs surgery in pd patients with standard programming (sp).

this is a randomized controlled trial aiming at comparing the efficacy of rp and sp in post-operative management of pd patients with dbs. enrolled patients will be randomly assigned to the rp or sp groups before surgery. after recording baseline data, regular programming sessions will be conducted through rp or sp. patients will be followed up in 6 months after implantation, with the main goal of the differences in motor symptom improvement between the two groups and the secondary goal of the difference in safety and economic benefits between both methods.

Eligibility criteria:
inclusion criteria: 1. adult primary parkinson's disease patients who meet the diagnostic criteria for parkinson's disease in china (2016 edition), aged 18-75 years 2. comply with the surgical indications of the "expert consensus on deep brain stimulation therapy for parkinson's disease in china (second edition)" and complete bilateral stn-dbs surgery 3. accurate lead position verified by postoperative ct examination 4. the implanted dbs device has remote programming function 5. having an internet connection at home or in the area that will receive remote postoperative management, and being able to participate in remote symptom assessment and remote programming 6. able to communicate fluently, and after education, i and my caregivers are proficient in using the patient client of the remote program control system 7. understand potential risks/benefits, agree to participate in the study, study procedures, agree to complete the study follow-up, and comply with the requirements of the study protocol. exclusion criteria: 1. the preoperative concise mental state examination (mmse) score of dbs indicates moderate or above cognitive impairment 2. severe complications after dbs surgery, such as stroke, encephalitis, wound infection, etc. 3. lack of cooperation, or inability to understand the experimental plan or provide informed consent for any reason 4. unable to provide stable network signal or unable to provide 4 × 1.5 m space for motion evaluation 5. other researchers believe that factors may not be suitable for research.

Keywords: telemedicine remote programming
rebif new formulation (rnf) quality of life (qol) study

Conditions: Relapsing Multiple Sclerosis

Summary: to evaluate the impact on quality of life (qol), tolerability, treatment satisfaction, and injection site redness rebif treated subjects with relapsing forms of ms who transition to a new formulation of rebif (rnf).


Eligibility criteria:
inclusion criteria: 1. subject with a relapsing form of ms; diagnosis of ms is in accordance with the mcdonald criteria 2. subject currently taking rebif 44mcg tiw, and has been on this treatment for at least 6 months (24 weeks) prior to study enrollment 3. subject currently using rebiject ii and 29 gauge needle 4. subject is between 18 and 60 years old inclusive 5. subject is able to read and understand english 6. subject is willing to follow study procedures 7. subject has given written informed consent and signed hipaa 8. female subjects must not be either pregnant or breast-feeding and must lack childbearing potential, as defined by either: i) being post-menopausal or surgically sterile, or ii) using a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, or condom with spermicide, for the duration of the study. (confirmation required within 30 days prior to start of the study) exclusion criteria: 1. use of any other injectable medications on a regular basis during the week prior to the screening period or during the screening or treatment periods. receiving a single injection for treatment or prophylaxis of a condition unrelated to the subject's multiple sclerosis or the subject's rebif® therapy (e.g., receiving a influenza or pneumococcus vaccination) is acceptable 2. subject receiving ms therapy in addition (i.e., combination therapy) to rebif® within 3 months prior to study enrollment or at any time during study protocol. 3. subjects who have previously been on rebif new formulation (rnf). 4. subject with progressive forms of multiple sclerosis (ms). 5. subject with history of any chronic pain syndrome. 6. subject has any other disease apart from ms that could better explain the subjects signs and symptoms. 7. subject has complete transverse myelitis or bilateral optic neuritis. 8. subjects that use any investigational drug or experimental procedure within 12 weeks of visit 1. 9. subject received oral or systemic corticosteroids or acth within 30 days of visit 1 (prior to enrollment). 10. subject has inadequate liver function, defined by a total bilirubin, aspartate aminotransferase (ast) or alanine aminotransferase (alt) or alkaline phosphatase \> 2.5 times the upper limit of the normal values. 11. subject has inadequate bone marrow reserve, defined as a white blood cell count less than 0.5 x lower limit of normal. 12. subject suffers from other current autoimmune disease. 13. subject suffers from major medical or psychiatric illness that in the opinion of the investigator creates undue risk to the subject or could affect compliance with the study protocol 14. subject is pregnant or attempting to conceive 15. visual or physical impairment that precludes completion of diaries and questionnaires.